Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07684599 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

StatusNot Yet Recruiting
PhasePhase 3
Started2026-09-03
View on ClinicalTrials.gov ↗
The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the physician's choice of immunotherapy (dostarlimab or pembrolizumab) alone, which represents the current standard of care. The study will also assess whether the drug combination is safe and tolerated well by participants compared to standard of care and will help us better understand its impact on Health-Related Quality of Life of participants.

Amendment history 1 change detected by DataLookout

2026-09-02
Interventions modified
Trial Details
NCT Number NCT07684599
Lead Sponsor GlaxoSmithKline
Collaborators: ENGOT, GOG, APGOT
Conditions Neoplasms, Endometrial
Enrollment 610 participants
Start Date 2026-09-03
Primary Completion 2029-07-23 (estimated)
Study Completion 2031-09-18 (estimated)
Updated on ClinicalTrials.gov 2026-09-01